Abstract:Pathological cardiac hypertrophy is a maladaptive response in a variety of organic heart disease (OHD), which is characterized by mitochondrial dysfunction that results from disturbed energy metabolism. SIRT3, a mitochondria‐localized sirtuin, regulates global mitochondrial lysine acetylation and preserves mitochondrial function. However, the mechanisms by which SIRT3 regulates cardiac hypertrophy remains to be further elucidated. In this study, we firstly demonstrated that expression of SIRT3 was decreased in Angiotension II (Ang II)‐treated cardiomyocytes and in hearts of Ang II‐induced cardiac hypertrophic mice. In addition, SIRT3 overexpression protected myocytes from hypertrophy, whereas SIRT3 silencing exacerbated Ang II‐induced cardiomyocyte hypertrophy. In particular, SIRT3‐KO mice exhibited significant cardiac hypertrophy. Mechanistically, we identified NMNAT3 (nicotinamide mononucleotide adenylyltransferase 3), the rate‐limiting enzyme for mitochondrial NAD biosynthesis, as a new target and binding partner of SIRT3. Specifically, SIRT3 physically interacts with and deacetylates NMNAT3, thereby enhancing the enzyme activity of NMNAT3 and contributing to SIRT3‐mediated anti‐hypertrophic effects. Moreover, NMNAT3 regulates the activity of SIRT3 via synthesis of mitochondria NAD. Taken together, these findings provide mechanistic insights into the negative regulatory role of SIRT3 in cardiac hypertrophy. Sirtuin 3 (SIRT3), a mitochondrial deacetylase that may play an important role in regulating cardiac function and a potential target for CHF.Support or Funding InformationThis work was supported by grants from the National Natural Science Foundation of China (No 81673433, No 81026548 and No 81273499), Team item of the Natural Science Foundation of Guangdong Province (NoS2011030003190)This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity

STAT3 Suppression is Involved in the Protective Effect of SIRT6 Against Cardiomyocyte Hypertrophy.

Roles of SIRT3 in Heart Failure: from Bench to Bedside.

SIRT3 improved peroxisomes-mitochondria interplay and prevented cardiac hypertrophy via preserving PEX5 expression

PARP1 Interacts with STAT3 and Retains Active Phosphorylated-Stat3 in Nucleus During Pathological Myocardial Hypertrophy.

SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation

Sirt3 Attenuates Angii-Induced Cardiac Fibrosis by Inhibiting Myofibroblasts Transdifferentiation Via Stat3-Nfatc2 Pathway

PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.

NMNAT3 is Involved in the Protective Effect of SIRT3 in Ang II-induced Cardiac Hypertrophy

SIRT3 Inhibits Ang II-induced Transdifferentiation of Cardiac Fibroblasts Through Β-Catenin/ppar-γ Signaling

SZC-6, a Small-Molecule Activator of SIRT3, Attenuates Cardiac Hypertrophy in Mice

SIRT 6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p 300

SIRT6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p300.

Mouse SIRT3 Attenuates Hypertrophy-Related Lipid Accumulation in the Heart Through the Deacetylation of LCAD.

SIRT1 Functions As an Important Regulator of Estrogen-Mediated Cardiomyocyte Protection in Angiotensin II-Induced Heart Hypertrophy

SIRT3: a Potential Target for CHF?

Activation of SIRT 3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-/ Smad 3 pathway

Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway.

SIRT3 involved in protecting heart by regulating mitochondrial protein deacetylation

Mouse Sirt3 Promotes Autophagy in AngII-induced Myocardial Hypertrophy Through the Deacetylation of FoxO1.

SIRT3 regulates cardiolipin biosynthesis in pressure overload-induced cardiac remodeling by PPARγ-mediated mechanism